ABBOTT LABORATORIES — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Abbott reported Q2 2026 comparable sales growth of 4.8% (reported 13.0%), raising full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58. The company completed the acquisition of Exact Sciences (cancer diagnostics) on March 23, 2026, which contributed materially to reported growth; excluding the acquisition and FX, underlying growth was modest. Abbott returned $2.1B to shareholders in Q2 via dividends and buybacks and reaffirmed full-year comparable sales guidance of 6.5%–7.5%.
Why this rating
EPS guidance raise of ~$0.07–0.02 midpoint is ~1% of $232B market cap; Exact Sciences acquisition is material acquisition but already announced prior; underlying organic growth modest at 4.8%.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.